Diagnostic accuracy of the new 2022 ACR/EULAR GCA and the 1990 ACR/EULAR classification criteria, with clinical diagnosis serving as the external criteria in all patients with GCA, as well as those with isolated cranial GCA, isolated LV-GCA, all LV-GCA and biopsy-proven GCA
| Sens (%) | Spec (%) | LR+ | LR− | AUC (95% CI) | ||
| All GCA (n=188) vs controls (n=131) | 2022 ACR/EULAR criteria | 92.6 | 71.8 | 3.28 | 0.1 | 0.928 (0.899 to 0.957) |
| 1990 ACR criteria | 53.2 | 80.2 | 2.68 | 0.58 | 0.719 (0.663 to 0.775) | |
| Isolated cranial GCA (n=83) vs controls (n=131) | 2022 ACR/EULAR criteria | 96.4 | 71.8 | 3.41 | 0.05 | 0.962 (0.930 to 0.993) |
| 1990 ACR criteria | 61.4 | 80.2 | 3.1 | 0.48 | 0.764 (0.699 to 0.829) | |
| Isolated LV-GCA (n=37) vs controls (n=131) | 2022 ACR/EULAR criteria | 62.2 | 71.8 | 2.21 | 0.53 | 0.691 (0.592 to 0.790) |
| 1990 ACR criteria | 18.9 | 80.2 | 0.95 | 1.01 | 0.554 (0.455 to 0.653) | |
| LV-GCA (with or without cranial GCA) (n=105) vs controls (n=131) | 2022 ACR/EULAR criteria | 89.5 | 71.8 | 3.17 | 0.15 | 0.901 (0.859 to 0.942) |
| 1990 ACR criteria | 46.7 | 80.2 | 2.36 | 0.66 | 0.683 (0.616 to 0.751) | |
| Biopsy-proven GCA (n=21) vs controls (n=131) | 2022 ACR/EULAR criteria | 100 | 71.8 | 3.55 | 0 | 0.989 (0.976 to 1) |
| 1990 ACR criteria | 95.2 | 80.2 | 4.81 | 0.06 | 0.931 (0.877 to 0.985) | |
| Biopsy-negative GCA (n=29) vs controls (n=131) | 2022 ACR/EULAR criteria | 100 | 71.8 | 3.55 | 0 | 0.970 (0.946 to 0.995) |
| 1990 ACR criteria | 55.2 | 80.2 | 2.79 | 0.31 | 0.735 (0.642 to 0.829) | |
ACR, American College of Rheumatology; AUC, area under the curve; GCA, giant cell arteritis; LR+, positive likelihood ratio; LR−, negative likelihood ratio; LV, large vessel; Sens, sensitivity; Spec, specificity.